UK advertising regulators have banned adverts for an at-home testosterone test kit promoted by Voy, after finding that claims linked to low testosterone were misleading. The decision by the Advertising Standards Authority places renewed attention on how online healthcare providers present diagnostic products directly to consumers.
The adverts concerned Voy’s at-home test kit and messaging around low testosterone. The regulator concluded that the claims did not meet the required standard for accuracy in advertising, leading to the ban. The ruling means the promotional material cannot continue in the form assessed by the watchdog. Voy operates in the growing field of digital health, where medical services and testing products are marketed through online channels rather than traditional clinical settings.
The case highlights a sensitive area of advertising regulation: health claims that may influence whether consumers decide to buy a test, seek treatment or interpret symptoms. Testosterone levels are a clinical matter that can vary between individuals and require appropriate medical assessment. For products sold for home use, regulators focus not only on the test itself but also on whether the surrounding marketing could give consumers an inaccurate impression of what the product can establish.
At-home testing has become more visible as healthcare providers expand online services, particularly in areas such as hormones, nutrition, fertility and men’s health. The convenience of remote testing can make services easier to access, but advertising rules require companies to avoid overstating what a kit can show or implying conclusions that are not properly supported. The ASA’s intervention underlines that digital healthcare advertising remains subject to the same standards of evidence and clarity as other medical marketing.
The ban is also a reminder that consumer-facing health technology depends heavily on trust. When medical claims are made in advertising, they must be presented with precision and adequate substantiation. For online providers, the ruling reinforces the need to ensure that promotional language does not blur the line between raising awareness of a health issue and suggesting a diagnosis or outcome that the evidence does not justify.


